SUPPLEMENTAL FIGURE 1. Titration data showing effect of varying amounts of cDNA transfected. Extended BRET (eBRET) kinetic profiles were generated with cells transfected with cDNA encoding CXCR2/Rluc8, β-arrestin2/Venus and α 1A AR at the indicated amounts in µg/well of a 6 well plate, and activated with 100 nM CXCL8 or 100 µM NE. Firstly, relatively high levels of CXCR2/Rluc8 cDNA were decreased while low levels of α 1A AR cDNA were increased and β-arrestin2/Venus cDNA was kept constant (A). Up to the point when receptor cDNA levels became similar, little change in CXCL8-induced BRET signal was observed (A). In contrast, as CXCR2/Rluc8 cDNA was titrated down further and α 1A AR cDNA titrated up further, the CXCL8-induced BRET signal decreased considerably (B). This was also the case with the NE-induced BRET signal (C, D). These data are consistent with either: i) the amount of CXCR2/Rluc8 cDNA present being a limiting factor for the BRET signal or ii) the ratio of receptor cDNA constructs being important. This was tested by varying the amount of receptor cDNA transfected, but maintaining a 1:1 ratio of CXCR2/Rluc8 to α 1A AR cDNA, and β-arrestin2/Venus cDNA constant (E, G). Perhaps surprisingly, it was found that the highest BRET signals were achieved with the lowest amounts of receptor cDNA. This is likely to be because the ratio of donor to acceptor becomes increasingly suboptimal as the amount of donor cDNA is increased relative to acceptor cDNA, in this case β-arrestin2/Venus. Furthermore, these data appear to confirm that the amount of CXCR2/Rluc8 present is not itself the limiting factor until the cDNA amount is less than 0.05 µg/well of a 6 well plate (E, G). In order to assess how little cDNA could be used, the amount of β-arrestin2/Venus cDNA was reduced to just 0.05 µg/well and receptor cDNA titrated down from 0.04 to 0.001 µg/well (F, H). Reasonable signals were still seen at a ratio of 0.005 : 0.05 : 0.005, whereas the signal became considerably noisier at a ratio of 0.001 : 0.05 : 0.001. These data illustrate that the NE-induced BRET signals indicative of heteromerization (G, H) are observed at very low cDNA levels, supporting the specificity of the signal. Finally, ligand-induced BRET saturation assays were carried out in terms of increasing the amount of acceptor cDNA while maintaining the amount of donor cDNA constant. It was found that both the CXCL8-induced (I) and NE-induced (J) BRET signals increased with increasing acceptor cDNA, saturating at 0.3 µg/well of a 6 well plate. SUPPLEMENTAL FIGURE 2. Specificity of the anti-CXCR2 antibody for the CXCR2 chemokine receptor. CHO cells expressing either CXCR2 (A) or CCR2 (B) chemokine receptors were immunostained with rabbit polyclonal antibodies to CXCR2 (red) with TO-PRO-3 (green) nuclear counterstaining. Positive immunostaining is observed in cells expressing CXCR2 receptors (A), but not in cells expressing CCR2 receptors (B) indicating specificity of the anti-CXCR2 antibody for the CXCR2 receptor. No staining was observed in mock-transfected cells (C). 40 x objective; scale bars, 50 µm. SUPPLEMENTAL FIGURE 3. β-arrestin2/Venus translocation studies on cells with or without untagged CXCR2. HEK293FT cells expressing β-arrestin2/Venus (A-C) or β-arrestin2/Venus and untagged CXCR2 (D-F) were treated with vehicle (A, D), 100 nM NE (B, E) or 100 nM CXCL8 (C, F) as indicated for 30 min. The localization of β-arrestin2/Venus (green) was then assessed by confocal microscopy. Nuclei were also visualized with Hoescht staining (blue). Scale bars, 10 µm.
